Posts Tagged ‘artificial intelligence’
Pilot program by IU and Davos Alzheimer’s Collaborative to test AI-powered cognitive screening at scale
How AI, Digital Screening Tools Can Help Flag Early Cognitive Decline (Health IT Analytics): Early diagnosis of Alzheimer’s and other dementias remains at the forefront of efforts to minimize the impact of these neurodegenerative diseases. But challenges such as increased life expectancy and the risks of aging, along with complexities in diagnosis and treatment resulting…
Read MorePrecision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform
Alto Neuroscience Raises $35M Series B Financing (FinsMes): Alto Neuroscience, a Los Altos, CA-based neuro-tech company which specializes in precision psychiatry, raises $35M Series B Financing … The company intends to use the funds to advance lead candidates into Phase 2b studies in major depressive disorder … Proceeds from the financing will also be used…
Read MoreAI-enabled chatbot Wysa receives FDA Breakthrough Device designation for patients with chronic pain, depression and anxiety
AI Behavior Health Chatbot App Fast-Tracked by FDA (Psychology Today): Recently the U.S. Food and Drug Administration (FDA) granted breakthrough device designation to Wysa’s AI-based digital mental health conversational agent that delivers cognitive behavioral therapy (CBT) via a smartphone to adults suffering from depression, anxiety, and chronic musculoskeletal pain
Read MoreGeisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia
Research collaboration will test novel algorithm’s effectiveness on Geisinger data (press release): Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the detection of cognitive impairment that could identify dementias, including Alzheimer’s disease (AD). If effective, the AI tool could potentially be developed…
Read MoreMapping ‘psychedelic trips’ in the brain to better direct their therapeutic effects
For the past several decades, psychedelics have been widely stigmatized as dangerous illegal drugs. But a recent surge of academic research into their use to treat psychiatric conditions is spurring a recent shift in public opinion. Psychedelics are psychotropic drugs: substances that affect your mental state. Other types of psychotropics include antidepressants and anti-anxiety medications.…
Read MoreBeacon Biosignals raises $27M to scale EEG, AI-based neurobiomarker discovery platform
Neurotech startup Beacon Biosignals scores $27M to bring AI to EEG analysis (MedCity News): Electroencephalography is a decades-old technique for capturing brain activity, data that are used to evaluate brain disorders. Beacon Biosignals is applying artificial intelligence to these tests, and the neurotechnology startup has found a ready market in pharmaceutical companies interested in assessing how…
Read More